血清CA125、CA19-9、CEA及SCC水平在子宫内膜癌患者中的诊断意义

The Value of CA125 CA199 CEA and SCC Assays in Endometrial Carcinomas

目的:探讨血清CA125、CA19-9、CEA及SCC联合测定在子宫内膜癌患者中的诊断及对病情评估的意义。方法:测定107例子宫内膜癌患者术前血清CA125、CA19-9、CEA及SCC水平,分析不同临床期别与4项标志物之间的关系。结果:4项肿瘤标志物中以血清CA125在子宫内膜癌患者中阳性率最高,达30.3%。联合测定阳性率升高,以CA125、CA19-9及CEA联合为最佳,阳性率可提高至48.5%。随着患者临床期别的增高,各项肿瘤标志物的中位数值及阳性率有升高趋势,Ⅱ～Ⅳ期患者显著高于Ⅰ期患者。血清CA125和(或)CA19-9≥40U/ml者,有50.3%的可能临床期别已达Ⅲ期。结论:子宫内膜癌患者术前联合测定CA125、CA19-9、CEA及SCC可协助正确诊断,有利于了解病情程度,制定合适的治疗方案。

Objective:To evaluate the value of preoperative serum CA1 2 5?CA19-9?CEA and SCC in the prediction of clinical outcome.Methods:Seru m CA125,CA19-9,CEA and SCC levels in107endometrial carcinoma patien ts were measured.Their correlations and clinical stages were analyzed.Results :Of the four tumor-associated antigens,the highest positive rate was serum CA125(30%).The positive rate raised when the markers were combinedly me asured.It reached48%when CA125,CA19-9and CEA were measured together .The median and pos-itive rate of each tumor-associated antigen escalated alo ng with the advancing of clinical stages.The:median and positive rate of each tumor-associated antigen of patients with clinical stageⅡ～Ⅳwere significantl y higher than those of patients with clinical stageⅠ.About 50%patients with serum CA125and/or CA19-9≥40ì/ml were probably reached clinical st ageⅢ.Conclusion:Serum tumor-associated antigen levels are helpful in diagno sis,clinical stage assessment and ther-apy plan of endometrial carcinoma.